Olympus Small Animal Imaging System

The OV100 is a new imaging system that allows researchers to observe fluorescent markers in live animals at the whole animal, organ, tissue, and single cell level, with a single optical instrument. The OV100 provides a 114:1 zoom ratio change and features superior optics for high resolution and efficiency of light collection. The OV100 integrates many basic needs of whole animal imaging including the removal of auto-fluorescence background and high performance in the NIR range up to 1000nm for fluorescence detection. The OV100 also allows the user to choose a CCD camera to meet the specific demands of their research i.e. high resolution, high speed, or low light sensitivity.

Features and Benefits

• High NA macro lens for low magnification, high light-gathering capacity
• 4-position objective turret using macro lenses and zoom lens for 114-fold magnification change
• Stabilized power supply for fluorescence illumination
• Magnification dependent light illumination paths for best result
• Four individual lenses parcentered and parfocal lenses
• Exchangeable excitation and emission filter turret
• Spectral unmixing and auto-fluorescence removal
• Automated XY stage for repositioning of animal or specimen scanning
• Choice of 2/3 inch CCD cameras optimized for application
• Experiment manager for reproducibility of experimental parameters
• Image data archive
• Anesthesia system and heating plate

Notice: The OV100 imaging system has many potential applications. Certain of these applications and materials used with them may require licensing under patents held by third parties. For example AntiCancer, Inc. (http://www.anticancer.com) and Xenogen Corporation (http://www.xenogen.com) each own several patents in the field of imaging cells genetically engineered to produce light-emitting compounds. Olympus has obtained a license from AntiCancer, such that non-profit entities purchasing the OV100 are licensed under AntiCancer U.S. Patent Nos. 6,232,523, 6,649,159, 6,235,968, 6,251,384, and 6,759,038 for non-commercial uses. Olympus' sale or other transfer of the OV100 imaging system does not convey any additional rights or licenses under third party patents. It is suggested that users of the OV100 imaging system consult with counsel to determine whether licensing of additional third party patents is required.